An Introduction to Axial Spondyloarthritis
Axial spondyloarthritis (axSpA) is an inflammatory disease of the axial skeleton, and causes significant back pain and disability. Treatment involves non-steroidal anti-inflammatory drugs (NSAIDs), physical therapy and exercise. Several anti-tumour necrosis factor (TNF) agents are approved for treatment of radiographic axSpA. Emerging therapeutic targets include interleukin (IL) -17 and the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway. Other emerging treatments include compounds that target IL-17A and IL-17F isoforms and granulocyte macrophage-colony stimulating factor (GM-CSF). However, many unmet needs remain, including optimising treatment response and biomarkers to identify patients with chronic back pain who may progress to axSpA.
Browse our selection of video highlights and short articles from the conference hub, which provide insights into the latest updates from major conferences, and a collection of peer-reviewed articles from the journal portfolio. These are complemented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Axial Spondyloarthritis Content
Denis Poddubnyy, ACR 2021: Secukinumab and HLA Subtypes in AxSpA
Prof. Denis Poddubny (Charité-Universitätsmedizin Berlin, Berlin, Germany) kindly took the time to speak with touchIMMUNOLOGY about the post-hoc analysis from the phase 3b SKIPPAIN trial (NCT03136861) aimed at exploring the potential association of HLA-B27 subtypes on the effect of secukinumab in patients with axSpA. This information is brought to you by Touch Medical Media and […]
Inna Gaydukova, EULAR 2021: Netakimab in Patients with Ankylosing Spondylitis with or without Sacroiliitis
It was a pleasure to meet with Professor Inna Gaydukova (North-Western State Medical University, St. Petersburg, Russia) to talk around the changes in ankylosing spondylitis activity in patients with and without sacroiliitis on netakimab treatment. ‘NETAKIMAB REDUCES ANKYLOSING SPONDYLITIS ACTIVITY IN PATIENTS WITH OR WITHOUT SACROILIITS ON MRI: RESULTS OF SUBANALYSIS OF PHASE 3 ASTERA […]
Peter Taylor, EULAR 2021: Highlights from the Congress
We had the pleasure to meet with our Editor-in-Chief, Professor Peter C Taylor (University of Oxford, Oxford, UK) who gave us some of the key highlights from this year’s European Congress of Rheumatology meeting, 2-5 June 2021. Questions What were the highlights of this year’s EULAR meeting? (0:11) Disclosures: Peter C Taylor reports receiving: Research grants […]
Anna Moltó, ACR 2020: TICOSPA Trial in Axial Spondyloarthritis
It was a delight to discuss with Anna Moltó (Hospital Cochin, Paris, France) the results of the TICOSPA trial (NCT03043846) which was designed to evaluate the benefit of treat-to-target in patients with axial spondyloarthritis. The abstract entitled ‘Cluster-randomized Pragmatic Clinical Trial Evaluating the Potential Benefit of a Tight-control and Treat-to-target Strategy in Axial Spondyloarthritis: The […]
Marina Magrey, ACR 2020 – Ixekizumab Response in Nr-axSpA Based on HLA-B27 and Disease Duration: The COAST-X Study
It was a pleasure to speak with Marina Magrey (Case Western Reserve University School of Medicine/ MetroHeath Medical Center, Cleveland, OH, USA) about the recent post-hoc analysis from the COAST X study (NCT02757352). The analysis was designed to evaluate the efficacy of ixekizumab at week 16 in patients with non-radiographic axial spondyloarthritis (nr-axSpA) with or […]
Marina Magrey, ACR 2020 – Prognosis and Unmet Need in Nr-axSpA
TouchIMMUNOLOGY was delighted to speak with Marina Magrey (Case Western Reserve University School of Medicine/ MetroHeath Medical Center, Cleveland, OH, USA) about non-radiographic axial spondyloarthritis (nr-axSpA), its prognosis and the unmet needs in its treatment. Disclosures: Marina Magrey has served as a consultant for Novartis, Eli Lilly, Pfizer, AbbVie, UCB and Janssen. She has also […]
Walter Maksymowych, ACR 2020 – Predictors of Response in Nr‑axSpA Treated with Certolizumab Pegol: The C-axSpAnd Study
Walter Maksymowych (University of Alberta, Alberta, Canada) talks to touchIMMUNOLOGY about the results of the C-axSpAnd Study (NCT02552212). This 52-week placebo-controlled study aimed to identify demographic or baseline characteristics of patients with nr-axSpA that could be predictive of achieving a clinical response to treatment with certolizumab pegol. The abstract entitled ‘Predictors of Response in Patients […]
Xenofon Baraliakos, ACR 2020 -Clinical Response Time Frame in Axial Spondyloarthritis Treated with Etanercept
Xenofon Baralikos (Ruhr-University, Bochum, Germany) discusses with touchIMMUNOLOGY the findings from the post hoc analysis of 4 RCT trials investigating the time frames of clinical response in patients with axial spondyloarthritis receiving etanercept. His abstract ‘Temporal Achievement of Clinical Response and Inactive Disease Status in Patients with Axial Spondyloarthritis Treated with Etanercept’ (ABSTRACT NUMBER: 0897) […]
Denis Poddubnyy, ACR 2020 – Secukinumab for AxSpA Spinal Pain: SKIPPAIN Study
It was an absolute pleasure to discuss the 24-week results from the SKIPPAIN study (NCT03136861) with Denis Poddubnyy (Charité-Universitätsmedizin Berlin, Berlin, Germany). The study, which is a phase IIIb trial, evaluated the efficacy and safety of secukinumab in reducing spinal pain and disease activity following a step-up dosing approach. His presentation entitled ‘Secukinumab Provides Significant Improvement […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!